BsAbs Targeting Immunomodulatory Checkpoints for Cancer Therapy

The development of immune checkpoint inhibitors (ICIs) has revolutionized the standard of care for cancer treatment, among which blocking the PD-1/PD-L1 signaling pathway is one of the most successful immunotherapeutic strategies to date.
Studies have shown that the development of novel bsAbs targeting immune checkpoints is an effective strategy to overcome these challenges. This type of bsAbs can address the compensatory mechanisms among multiple immune checkpoints by blocking them, thereby enhancing therapeutic efficacy. Furthermore, bsAbs can more precisely bridge immune cells and tumor cells decrease adverse reactions as well as drug dosage.
To support relevant research, we have developed over 500 products for immune checkpoint proteins, along with functional cell lines, inhibitor screening kits, and PK assay kits. This suite of products meets the needs of the entire workflow—from immunology studies, antibody screening and characterization, and stability determination to late-stage production quality control—helping to accelerate the research and development of immunotherapies.
Click to View More Detailed Information icon
The bsAbs targeting immunomodulatory checkpoints

The bsAbs targeting immunomodulatory checkpoints. The checkpoint-targeted bsAbs are mainly divided into three categories: targeting dual inhibitory checkpoints (①); targeting co-stimulatory and inhibitory checkpoints (②); and targeting immunomodulatory checkpoints and non-checkpoint targets (③④).
Source:doi: 10.20892/j.issn.2095-3941.2023.0002

Classification of BsAbs Targeting Immune Checkpoints

BsAbs targeting immune checkpoints can be mainly classified into the following types:
Targeting dual co-inhibitory immune checkpoints
Targeting dual co-inhibitory immune checkpoints
Targeting dual co-stimulatory immune checkpoints
Targeting dual co-stimulatory immune checkpoints
Targeting co-stimulatory and co-inhibitory immune checkpoints
Targeting co-stimulatory and co-inhibitory immune checkpoints
Targeting immune checkpoints, cytokines, and their receptors
Targeting immune checkpoints, cytokines, and their receptors
Targeting immune checkpoints and TAAs
Targeting immune checkpoints and TAAs
Targeting immune checkpoints and other non-immune checkpoints
Targeting immune checkpoints and other non-immune checkpoints

Validation Data

SEC-MALS Validation for Protein Structure and Purity
SEC-MALS Validation for Protein Structure and Purity

The purity of Human CTLA-4, His Tag (Cat. No. CT4-H52H9) is more than 90% and the molecular weight of this protein is around 45-60 kDa verified by SEC-MALS.

SEC-MALS Validation for Protein Structure and Purity

The purity of Biotinylated Human 4-1BB, His,Avitag (Cat. No. 41B-H82E6) is more than 90% and the molecular weight of this protein is around 25-35 kDa verified by SEC-MALS.

The binding activity to bsAbs was verified by ELISA
The binding activity to bsAbs was verified by ELISA

Immobilized Human PD-1, His Tag (Cat. No. PD1-H5221) at 5 μg/mL, add increasing concentrations of Cadonilimab (PD-1 x CTLA-4 bispecific antibody) and then add Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) at 0.2 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) with sensitivity of 2.99 ng/mL (Routinely tested).

Request Protocol

The binding activity to bsAbs was verified by ELISA

Immobilized Human VEGF165, His Tag (Cat. No. VE5-H5248) at 2 μg/mL, add increasing concentrations of Ivonescimab and then add Biotinylated Human PD-1 Protein, Avitag,His Tag (Cat. No. PD1-H82E4) at 2 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) with sensitivity of 2.17 ng/mL (Routinely tested).

Request Protocol

The binding activity to Abs was verified by ELISA
The binding activity to Abs was verified by ELISA

Immobilized Human LAG-3, His Tag (Cat. No. LA3-H5222) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human LAG3 Antibody, Human IgG1 with a linear range of 0.2-4 ng/mL (QC tested).

Request Protocol

The binding activity to Abs was verified by ELISA

Immobilized Human PD-1, His Tag (Cat. No. PD1-H5221) at 2 μg/mL (100 μL/well) can bind Nivolumab with a linear range of 0.1-3 ng/mL (Routinely tested).

Request Protocol

The binding activity to Abs was verified by BLI/SPR
The binding activity to Abs was verified by SPR/BLI

Loaded Anti-OX40 MAb(Human IgG1) on AHC Biosensor, can bind Human OX40 Protein, His Tag (Cat. No. OX0-H5224) with an affinity constant of 6.03 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Request Protocol

The binding activity to Abs was verified by SPR/BLI

Anti-LAG-3 MAb (Human IgG1) captured on CM5 chip via Anti-Human IgG Fc antibodies surface, can bind Human LAG-3, His Tag (Cat. No. LA3-H5222) with an affinity constant of 4.57 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Request Protocol

Neutralizing Antibody Screening
Neutralizing Antibody Screening

Serial dilutions of Human TIGIT Neutralizing antibody were added into Human TIGIT, Fc Tag (Cat. No. TIT-H5254): Biotinylated Human CD155, Fc,Avitag (Cat. No. CD5-H82F6) binding reactions. The half maximal inhibitory concentration (IC50) is 0.55834 μg/mL (Routinely tested).

Request Protocol

Neutralizing Antibody Screening

FACS analysis shows that the binding of Human SIRP alpha, His Tag (Cat. No. SIA-H5225) to Jurkat expressing CD47 was inhibited by increasing concentration of neutralizing Anti-CD47 antibody. The concentration of SIRP alpha used is 1 μg/mL.

Request Protocol
Pharmacokinetic Analysis - PK Analysis
Pharmacokinetic Analysis - PK Analysis

Quantitative Analysis of CTLA-4 x OX40 Bispecific Antibody in Human Serum by Intact Assay. Immobilized Human OX40 Protein, His Tag (MALS verified) (Cat. No. OX0-H5224) at 2 μg/mL, add increasing concentrations of CTLA-4 x OX40 bispecific antibody in 50% Human serum and then add Biotinylated Human CTLA-4, His, Avitag (Cat. No. CT4-H82E3) at 0.2 μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 4 ng/mL (Intact assay, Routinely tested).

Request Protocol

Pharmacokinetic Analysis - PK Analysis

Quantitative Analysis of CTLA-4 x OX40 Bispecific Antibody in Human Serum by Intact Assay Immobilized Human CTLA-4, His Tag, active dimer (Cat. No.CT4-H52H9) at 2 μg/mL, add increasing concentrations of CTLA-4 x OX40 Bispecific Antibody in 50% Human serum and then add Biotinylated Human OX40, Avitag,His Tag(Cat. No. TN4-H82E4) at 1 μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 4 ng/mL (Intact assay, Routinely tested).

Request Protocol

Resource

  • Background
  • Classification of BsAbs Targeting Immune Checkpoints
  • Validation Data
  • Resource
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호